The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 5.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 7% above its long-term trend line with momentum reading bearish. Over the past year the shares are down 9%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (7 analysts) rates it buy, with a mean price target of $26.
NovoCure Limited
NVCR · Nasdaq · USD · Market cap $1.3B · 1,605 employees
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Fr…
FAIL · Does not pass the screenPrice as of 17 Nov 2026Daily close, not a live quote
Screened 2026-11-17 · the tape above runs as of 07:15 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price11.14 USD at the 17 Nov 2026 close
- Our value readUndervalued vs our fair value, as of 17 Nov 2026
- Our regime readDistribution, as of 15 Nov 2026
- Ethical screenDoes not pass
- OptionsOpen interest leans to puts (put/call 185.80)
- Last reviewed17 Nov 2026 (1 day ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: $15.00 to $22.28, base estimate $20.00 (screen dated 2026-11-17).
- Trend Distribution
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 185.80, read 2026-11-14
- Ethical does not pass the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its distribution label.
NovoCure Limited holds its Distribution at $11.14. Consolidating, no directional conviction, held for 53 days.
| Phase | Distribution · caution |
| Quantitative state | Consolidating, no directional conviction, held for 53 days |
| Price at the screen | $11.14 |
| Valuation | N/A trailing · -15.31 forward price to earnings |
| Values screen | FAIL · score 70.0 |
| Beta | 1.08 |
Five Screens, Shown in Full
Does not pass. Interest-bearing securities
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 30.88% | Below 33% | Interest-bearing debt is just 30.9% of its assets, well under the one-third ceiling: it does not run on borrowed money. | Pass |
| Interest-bearing cash | 44.03% | Below 33% | Interest-bearing cash and securities are 44.0% of assets, above the one-third limit. | Fail |
| Receivables | 22.75% | Below 49% | Money owed to the company is 22.7% of assets, under the 49% limit. | Pass |
| Revenue purity | 1.96% | Below 5% | Only 2.0% of revenue comes from non-compliant sources, under the 5% line. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadWhy It Falls Short, in Plain English
NovoCure's business is fine, but its cash and interest-bearing securities are about 44% of its assets, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-17. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when NVCR's ethical verdict changes
Today NVCR does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Our analysis reads Undervalued vs our fair value, as of 17 Nov 2026: it trades at roughly a 44% discount to our $20.00 fair value, 15.70% revenue growth.
How a fair value is estimated: discounted cash flow (DCF).
Fair value range in USD, drawn from the 2026-11-17 screen. The gold marker is the market price at the same screen. A 44.3% discount to the base estimate.
Third-party analyst targets: 7 covering, consensus Buy. The average target sits +80% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & ProjectionsWhere our models see it going: fair-value estimate $20.00, with a range of $15.00 to $22.28, dated to the 2026-11-17 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsWhy it stands out
A 16%-growth business trading at just -15.3x forward earnings. That is a 44% discount to our $20.00 fair value: the market is pricing it cautiously while the fundamentals argue otherwise. 7 analysts rate it Buy with a $20.00 average target, about 80% above the screened price.
| Forward P/E | -15.3x |
| EPS, trailing | -1.06 |
| EPS, forward | -0.73 |
| Revenue growth | +15.7%steady growth |
| Profit margin | -16.8%currently unprofitable |
| Return on equity | -35.2%not currently earning a positive return on equity |
| FCF yield | 0.69% |
| Debt to equity | 0.66moderate, manageable leverage |
| Current ratio | 2.49comfortably covers its short-term bills |
| Beta | 1.08moves a little more than the market |
| Short interest, float | 0.15% |
| 52-week range | 9.82 - 21.45 |
| Market cap | $1.3B |
| Employees | 1,605 |
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; its business and earnings are exposed to Switzerland and to currency swings.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeNVCR trades on Nasdaq (the company is based in Switzerland). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 12.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 7% above its long-term trend line with momentum reading bearish. Over the past year the shares are down 9%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (7 analysts) rates it buy, with a mean price target of $26.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 13.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 10% above its long-term trend line with momentum reading neutral. Over the past year the shares are down 9%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (7 analysts) rates it buy, with a mean price target of $26.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 12.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 10% above its long-term trend line with momentum reading neutral. Over the past year the shares are down 9%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (7 analysts) rates it buy, with a mean price target of $26.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 5.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 0% above its long-term trend line with momentum reading bearish. Over the past year the shares are down 9%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (7 analysts) rates it buy, with a mean price target of $26.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 11.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 33% above its long-term trend line with momentum reading neutral. Over the past year the shares are down 9%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (7 analysts) rates it buy, with a mean price target of $26.
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 8.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 33% above its long-term trend line with momentum reading neutral. Over the past year the shares are down 9%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (7 analysts) rates it buy, with a mean price target of $26.
The framework has shifted from distribution to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 13.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 33% above its long-term trend line with momentum reading neutral. Over the past year the shares are down 9%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (7 analysts) rates it buy, with a mean price target of $26.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 10.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 33% above its long-term trend line with momentum reading neutral. Over the past year the shares are down 9%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (7 analysts) rates it buy, with a mean price target of $26.
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 33% above its long-term trend line with momentum reading neutral. Over the past year the shares are down 9%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (7 analysts) rates it buy, with a mean price target of $26.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- JAMA Network Open Publishes Quality of Life and Pain Outcomes Data from Phase 3 PANOVA-3 Trial of Novocure’s Tumor Treating Fields for Pancreatic Cancer Yahoo Finance · 5d ago
- NovoCure (NVCR) Stock May Trade At A Discount Despite FDA Setback Yahoo Finance · 5d ago
- FDA Rejects NovoCure’s Optune Mya for Lung Cancer Brain Metastases. Here's What It Means for Investors. Yahoo Finance · 8d ago
- Novocure denied FDA approval for metastatic cancer treatment Yahoo Finance · 9d ago
- Novocure Provides Regulatory Update on U.S. FDA Premarket Approval Application for Optune Mya® for Brain Metastases from Non-Small Cell Lung Cancer Yahoo Finance · 9d ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $18.10 | -7.6% | · | $924 | -7.6% |
| 2 months | $10.58 | +58.1% | · | $1,581 | +58.1% |
| 3 months | $12.01 | +39.3% | · | $1,393 | +39.3% |
| 6 months | $13.66 | +22.5% | · | $1,225 | +22.5% |
| 1 year | $18.38 | -9.0% | · | $910 | -9.0% |
| 2 years | $21.46 | -22.0% | · | $780 | -22.0% |
| 3 years | $42.76 | -60.9% | · | $391 | -60.9% |
| 5 years | $216.28 | -92.3% | · | $77 | -92.3% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever NVCR does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.